Page 102 - Read Online

Dixit et al. J Cancer Metastasis Treat 2022;8:47 https://dx.doi.org/10.20517/2394-4722.2022.70 Page 11 of 11

signaling axis. Mol Ther Nucleic Acids 2021;24:669-81. DOI PubMed PMC
41. Ivanov SV, Goparaju CM, Lopez P, et al. Pro-tumorigenic effects of miR-31 loss in mesothelioma. J Biol Chem 2010;285:22809-17.
DOI PubMed PMC
42. Moody HL, Lind MJ, Maher SG. MicroRNA-31 regulates chemosensitivity in malignant pleural mesothelioma. Mol Ther Nucleic
Acids 2017;8:317-29. DOI PubMed PMC
43. Matsumoto S, Nabeshima K, Hamasaki M, Shibuta T, Umemura T. Upregulation of microRNA-31 associates with a poor prognosis of
malignant pleural mesothelioma with sarcomatoid component. Med Oncol 2014;31:303. DOI PubMed
44. Khodayari N, Mohammed KA, Goldberg EP, Nasreen N. EphrinA1 inhibits malignant mesothelioma tumor growth via let-7
microRNA-mediated repression of the RAS oncogene. Cancer Gene Ther 2011;18:806-16. DOI PubMed
45. Truini A, Coco S, Nadal E, et al. Downregulation of miR-99a/let-7c/miR-125b miRNA cluster predicts clinical outcome in patients
with unresected malignant pleural mesothelioma. Oncotarget 2017;8:68627-40. DOI PubMed PMC
46. Khodayari N, Mohammed KA, Lee H, Kaye F, Nasreen N. MicroRNA-302b targets Mcl-1 and inhibits cell proliferation and induces
apoptosis in malignant pleural mesothelioma cells. Am J Cancer Res 2016;6:1996-2009. PubMed PMC
47. Ramírez-Salazar EG, Salinas-Silva LC, Vázquez-Manríquez ME, et al. Analysis of microRNA expression signatures in malignant
pleural mesothelioma, pleural inflammation, and atypical mesothelial hyperplasia reveals common predictive tumorigenesis-related
targets. Exp Mol Pathol 2014;97:375-85. DOI PubMed
48. Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer
Discov 2018;8:1548-65. DOI PubMed PMC
49. Johnson TG, Schelch K, Cheng YY, et al. Dysregulated expression of the MicroRNA miR-137 and its target YBX1 contribute to the
invasive characteristics of malignant pleural mesothelioma. J Thorac Oncol 2018;13:258-72. DOI PubMed
50. Reid G, Kao SC, Pavlakis N, et al. Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent
thoracic cancer. Epigenomics 2016;8:1079-85. DOI PubMed
51. Majumder P, Singh A, Wang Z, et al. Surface-fill hydrogel attenuates the oncogenic signature of complex anatomical surface cancer in
a single application. Nat Nanotechnol 2021;16:1251-9. DOI PubMed PMC
52. Napoli F, Rapa I, Izzo S, et al. Micro-RNA-215 and -375 regulate thymidylate synthase protein expression in pleural mesothelioma
and mediate epithelial to mesenchymal transition. Virchows Arch 2022;481:233-44. DOI
53. Tanaka N, Toyooka S, Soh J, et al. Downregulation of microRNA-34 induces cell proliferation and invasion of human mesothelial
cells. Oncol Rep 2013;29:2169-74. DOI PubMed
54. Muraoka T, Soh J, Toyooka S, et al. The degree of microRNA-34b/c methylation in serum-circulating DNA is associated with
malignant pleural mesothelioma. Lung Cancer 2013;82:485-90. DOI PubMed
55. Munson PB, Hall EM, Farina NH, Pass HI, Shukla A. Exosomal miR-16-5p as a target for malignant mesothelioma. Sci Rep
2019;9:11688. DOI PubMed PMC
56. Monaco F, De Conti L, Vodret S, et al. Force-feeding malignant mesothelioma stem-cell like with exosome-delivered miR-126
induces tumour cell killing. Transl Oncol 2022;20:101400. DOI PubMed PMC